Movement Disorders

Neurology News Network for the week ending December 18, 2021. [WATCH TIME: 3 minutes]

Pharma Two B anticipates filing a new drug application to the FDA for the investigational treatment in 2022.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 17, 2021.

Over a 10-year period, apomorphine sublingual film was projected to be dominant in 70% of patients compared with apomorphine hydrochloride injection and 71% vs levodopa inhalation powder.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 10, 2021.

Here's what is coming soon to NeurologyLive®.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 3, 2021.

The approval expands the devices existing indications for medication-refractory essential tremor and tremor-dominant Parkinson disease.

Expert clinicians offer their perspectives on transitional care in pediatric MS, a biomarker for SUDEP, and a novel approach to narcolepsy, among other topics.

As more organizations begin to adopt palliative care practices for patients with Parkinson disease, some may turn to the implemented plans of Cleveland Clinic as an example to follow.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 26, 2021.

Closing out his review of on-demand therapies for morning OFF episodes in Parkinson disease, Peter A. LeWitt, MD, shares practical advice for community neurologists.

Peter A. LeWitt, MD, discusses the use of sublingual apomorphine hydrochloride compared with its subcutaneous formulation in Parkinson disease.

Expert neurologists provide insight on how to decide on an on-demand therapy for Parkinson’s disease and provide some general advice.

Key opinion leaders explain the use of sublingual apomorphine and trimethobenzamide for Parkinson’s disease.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 19, 2021.

Expert insight on the mechanism of action and use of subcutaneous apomorphine hydrochloride in patients with Parkinson disease.

Peter A. LeWitt, MD, considers the mechanism of action and use of levodopa inhalation powder in patients with Parkinson disease.

The guideline updates previous recommendations for dopaminergic medications published in 2002, integrating new medications and formulations.

Patients with REM sleep percentage less than 15% were associated with poorer horizontal optokinetic nystagmus grades and more severe illness.

A panel of experts debate the disadvantages and side effects of apomorphine therapies for Parkinson’s disease.